Bile Duct Cancer Market Report 2026

The bile duct cancer market size has grown strongly in recent years. It will grow from $2.59 billion in 2025 to $2.82 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to limited early diagnostic capabilities, rising incidence of liver and bile duct disorders, expansion of oncology treatment centers, increasing use of chemotherapy regimens, growing awareness of rare cancers.

The bile duct cancer market size is expected to see strong growth in the next few years. It will grow to $3.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to increasing investment in precision oncology research, rising adoption of immunotherapy treatments, expansion of advanced diagnostic screening programs, growing use of ai-assisted cancer diagnostics, increasing focus on personalized cancer treatment pathways. Major trends in the forecast period include increasing adoption of targeted and immunotherapy treatments, rising use of advanced diagnostic imaging techniques, growing integration of multidisciplinary cancer care models, expansion of precision oncology approaches, enhanced focus on early detection and staging.

The increasing incidence of liver diseases is anticipated to boost the bile duct cancer market in the future. Liver diseases encompass various conditions that impair the liver's normal functioning, such as hepatitis, cirrhosis, fatty liver disease, and liver cancer. This surge in liver diseases stems mainly from factors like higher alcohol intake, poor dietary habits, obesity, viral infections including hepatitis, and insufficient physical exercise. Bile duct cancer aids in comprehending liver diseases by underscoring the vital role of bile ducts in liver operations, since their blockage or malfunction frequently triggers liver complications like jaundice and cholestasis. For example, in July 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental body, reported that the worldwide prevalence of chronic liver diseases, including non-alcoholic fatty liver disease (NAFLD), hit about 30.2%, rising from 26% in prior estimates, signaling an expanding group vulnerable to bile duct cancer. Thus, the growing prevalence of liver diseases is fueling the expansion of the bile duct cancer market.

Major companies active in the bile duct cancer market are prioritizing innovative treatments, like targeted therapies, to enhance patient outcomes, minimize side effects, and provide fresh options for those facing this rare and difficult cancer. Targeted therapies zero in on specific genes, proteins, or molecules that fuel cancer cell growth. By disrupting the mechanisms that enable cancer proliferation, these therapies seek to halt tumor progression, cut down on adverse effects, and boost overall efficacy. For example, in August 2023, Taiho Pharmaceutical Co. Ltd., a pharmaceutical firm based in Japan, introduced FGFR Inhibitor LYTGOBI Tablets 4 mg. The tablet form of LYTGOBI delivers a user-friendly oral dosing method, improving patient adherence and simplifying therapy. This introduction offers a novel treatment avenue for individuals with advanced or metastatic bile duct cancer, especially those with FGFR2 fusion or rearrangement mutations, meeting a key gap in oncology care.

In July 2023, Lucence, a US-based precision health company, teamed up with Innovent Biologics Inc. Through this collaboration, Lucence seeks to bolster its molecular diagnostic capabilities by integrating Innovent Biologics' advanced therapies - like targeted options for bile duct cancer - into its testing services. Innovent Biologics Inc. is a China-based biotechnology firm specializing in the research, development, production, and commercialization of innovative biopharmaceuticals.

Major companies operating in the bile duct cancer market are AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Merck & Co. Inc., Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Genentech Inc., Jazz Pharmaceuticals plc, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Mirati Therapeutics Inc., RenovoRx Inc., Spectrum Pharmaceuticals Inc., Specialised Therapeutics Pty Ltd, Taiho Pharmaceutical Co. Ltd.

North America was the largest region in the bile duct cancer market in 2025. The regions covered in the bile duct cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bile duct cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the bile duct cancer market by increasing costs of imported diagnostic imaging systems, biopsy tools, oncology drugs, radiation equipment, and targeted therapy components. Cancer treatment centers in North America and Europe are most affected due to reliance on imported advanced medical technologies, while Asia-Pacific faces higher costs in expanding oncology infrastructure. These tariffs are increasing treatment expenses and limiting access to advanced therapies. However, they are also supporting domestic pharmaceutical manufacturing, regional oncology research initiatives, and localized production of cancer diagnostic and treatment technologies.

The bile duct cancer market research report is one of a series of new reports that provides bile duct cancer market statistics, including bile duct cancer industry global market size, regional shares, competitors with a bile duct cancer market share, detailed bile duct cancer market segments, market trends and opportunities, and any further data you may need to thrive in the bile duct cancer industry. This bile duct cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cholangiocarcinoma is a rare cancer that develops in the bile ducts, the tubes transporting bile from the liver to the gallbladder and small intestine. It is usually detected at advanced stages and may cause symptoms like jaundice, weight loss, and abdominal pain.

Bile duct cancer primarily consists of extrahepatic bile duct cancer (ECC) and intrahepatic bile duct cancer (ICC). Extrahepatic bile duct cancer (ECC) arises in the bile ducts located outside the liver, usually where these ducts leave the liver and link to the small intestine. Treatment options for it encompass surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. It gets classified by stage as localized, regional, or distant, with diagnosis generally relying on imaging tests, biopsy, blood tests, and serving various end users like hospitals, clinics, ambulatory surgical centers, and cancer research institutes.

The bile duct cancer market includes revenues earned by entities by services such as diagnostic services, treatment services, clinical trials, and research services, and related products such as pharmaceutical products, diagnostic products, and supportive care products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.